###### Strengths and limitations of this study

-   To the best of our knowledge, this is the first published study to investigate the risk of patients with schizophrenia with chronic kidney disease (CKD) based on the population database.

-   In a nationwide, matched cohort study, the selection bias could be minimised.

-   Misclassification of diseases might exist in such claim data on the basis of the International Classifications of Disease Ninth Edition (ICD-9), Clinical Modification codes.

-   A longer follow-up is needed to clarify the long-term risk for patients with schizophrenia developing CKD in this population.

Introduction {#s1}
============

Schizophrenia, a chronic mental illness, has an approximately 1% lifetime prevalence in the global population,[@R1] which results in marked behavioural disturbances and functional impairment.[@R2] A higher risk for diabetes mellitus, hyperlipidaemia, obesity and consequent cardiovascular or cerebrovascular diseases has been noted in patients with schizophrenia, along with a higher mortality related to these diseases---as much as two to three times higher in comparison with the general population.[@R3]

However, whether other health problems, such as CKD, are related to schizophrenia is less discussed. A higher prevalence of CKD was found in developed countries, and identified risk factors include diabetes mellitus, hypertension and the use of various medications.[@R4] Other medical or mental illnesses that could be contributing to CKD remain unknown.

The Taiwan National Health Insurance Research Dataset (NHIRD) was used to establish whether there is an association between schizophrenia and CKD during a subsequent 3-year follow-up period, from the index date. The National Health Insurance (NHI) Programme was initiated in Taiwan in 1995, and as of June 2009 there were 22 928 190 people enrolled, exceeding 99% of Taiwan\'s population, who contracted with 97% of the medical providers in Taiwan.[@R5] The diagnostic coding used for the NHI is according to the International Classiﬁcation of Disease, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic criteria.[@R6] Each diagnosis of schizophrenia or CKD was made by board-certified psychiatrists or nephrology specialists, and psychiatric experts from the Bureau of National Health Insurance randomly review the charts of 1 per 100 ambulatory cases, and 1 per 20 inpatient claimed cases, in order to verify the accuracy of the diagnosis.[@R7] In addition, several Taiwan studies have demonstrated the high accuracy and validity of the diagnoses in the NHIRD.[@R8]

Methods {#s2}
=======

Database {#s2a}
--------

This study used the NHIRD, which is released by the Taiwan National Health Insurance (NHI) programme. The NHIRD is open to scientists for research purposes and covers 99% of Taiwan\'s 23 million citizens. The research used the Longitudinal Health Insurance Database 2005 (LHID 2005), which consists of all the original claims data of one million beneficiaries selected from the total registry in 2005 for the analyses. There were no statistically significant differences in age and sex between the LHID and all enrollees. In order to protect individual privacy, the identities of individuals included in this database were all encrypted. The NHI medical claims database includes ambulatory care, inpatient care, outpatient care and prescription drugs. Patients' diagnoses are coded using the 'International Classification of Diseases, 9th Revision, Clinical Modification' (ICD-9-CM).

Study population {#s2b}
----------------

We identiﬁed adult (≥18 years) patients with a ﬁrst-time diagnosis of schizophrenia (ICD-9-CM 295.xx) between 1 January 2003 and 31 December 2007. Patients with schizophrenia or CKD (ICD-9-CM 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 753, 403, 404, 2504, 2741, 4401, 4421, 4473, 5724, 6421 or 6462) before the index date were further excluded. The initial diagnosis date was defined as the index date of entry into the schizophrenia cohort ([figure 1](#BMJOPEN2014006777F1){ref-type="fig"}). In Taiwan, the diagnosis of CKD follows the criteria of 'Kidney Disease: Improving Global Outcomes (KDIGO)'. CKD is defined as kidney damage as albumin-to-creatinine ratio \>30 mg/g in two of three spot urine specimens, or glomerular filtration rate (GFR) \<60 mL/min/1.73 m^2^, for 3 months or more, irrespective of the cause.[@R11]

![Sampling from the National Health Insurance Research Dataset (NHIRD).](bmjopen2014006777f01){#BMJOPEN2014006777F1}

During 2003--2007, the NHIRD database used included 2338 patients with schizophrenia. We identified one such control patient with the most similar demographic characteristics. Covariates included gender, age group (18--29, 30--39, 40--49, 50--59, 60--69, ≥70 years), geographical areas (north, central, south and east of Taiwan), urbanisation level (level 1--4) and monthly income groups (NTD; \<18 000, 18 000--34 999, ≥35 000). The urbanisation of a patient's home city was defined by population and certain indicators of the city\'s level of development. Level 1 urbanisation was defined as having a population greater than 1 250 000 people, and a specific status of political, economic, cultural and metropolitan development. Level 2 urbanisation was defined as having a population between 500 000 and 1 250 000, and an important role in Taiwan\'s political system, economy and culture. Urbanisation levels 3 and 4 were defined as having a population between 150 000 and 500 000 and a population less than 150 000, respectively.[@R12]

After matching, 7014 were found to be without schizophrenia (1:3) among a total of 9352 sampled patients. All patients were followed up within 3 years or those diagnosed with CKD. Comorbidities included diabetes (ICD-9-CM 250, 250.33), hypertension (ICD-9-CM 401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 405.1, 405.9), hyperlipidaemia (ICD-9-CM 272.x), obesity (ICD-9-CM 278), heart disease (ICD-9-CM 410--429) and non-steroidal anti-inflammatory drugs (NSAIDs) usage.

Statistical analysis {#s2c}
--------------------

Microsoft SQL Server 2008 software was used for data management and analysis. All statistical methods were performed using the Statistical Analysis Systems software package (Release 9.3; SAS Institute, Cary, North Carolina, USA). A two-sided p value with less than 0.05 was considered statistically significant. The χ^2^ test was used to analyse data for categorical variables including gender, age group, geography, urbanisation level, monthly income, comorbidities and NSAIDs usage from the data set prescription records. Multivariate analysis was conducted using Cox proportional hazards regression models to estimate the effects of risk factors on the HRs, and the 95% CI, for CKD.[@R13]

Results {#s3}
=======

We identified 2338 patients with schizophrenia, and 7014 without schizophrenia, among a total of 9352 sampled patients by using 1:3 matched. [Table 1](#BMJOPEN2014006777TB1){ref-type="table"} shows the distributions of demographic characteristics and medical comorbidities among patients with and without schizophrenia in Taiwan. Schizophrenia occurred more frequently in the age group of 18--29 years (31.61%) than in the other five groups. Patients with schizophrenia generally had a lower economic status (67.19%), urbanisation level (45.34%) and lived in the north (45.60%). A comparison with controls revealed that patients with schizophrenia were more likely to have the comorbidities of diabetes mellitus (9.32 vs 7.13%, p\<0.001), hypertension (17.96% vs 15.64%, p\<0.05) and hyperlipidaemia (11.63% vs 10.92%, p\<0.05). Patients with schizophrenia were more likely to take NSAIDs (41.06% vs 33.73%, p\<0.001).

###### 

Distribution of gender, age group and comorbidity in individuals with and without schizophrenia

                       Number of (%) of individuals   p Value        
  -------------------- ------------------------------ -------------- ---------
  Gender               1                                             
   Female              1120 (47.9)                    3360 (47.9)    
   Male                1218 (52.1)                    3654 (52.1)    
  Age group            1                                             
   18--29              739 (31.61)                    2217 (31.61)   
   30--39              576 (24.64)                    1728 (24.64)   
   40--49              502 (21.47)                    1506 (21.47)   
   50--59              255 (10.91)                    765 (10.91)    
   60--69              128 (5.47)                     384 (5.47)     
   ≥70                 138 (5.9)                      414 (5.9)      
  Income               \<0.001                                       
   \<18 000            1571 (67.19)                   3155 (44.98)   
   18 000--34 999      673 (28.79)                    2591 (36.94)   
   ≥35 000             94 (4.02)                      1268 (18.08)   
  Urbanisation\*       \<0.001                                       
   1                   526 (22.5)                     1980 (28.23)   
   2                   169 (7.23)                     597 (8.51)     
   3                   583 (24.94)                    1757 (25.05)   
   4                   1060 (45.34)                   2680 (38.21)   
  Geography            \<0.001                                       
   North               1067 (45.60)                   3669 (52.30)   
   Central             461 (19.70)                    1224 (17.50)   
   South               734 (31.40)                    1984 (28.30)   
   East                76 (3.30)                      137 (2.00)     
  Comorbidity                                                        
   Hypertension        420 (17.96)                    1097 (15.64)   \<0.05
   Diabetes mellitus   218 (9.32)                     500 (7.13)     \<0.001
   Dyslipidaemia       272 (11.63)                    766 (10.92)    0.342
   Obesity             27 (1.20)                      39 (0.60)      \<0.05
   Heart disease       343 (14.70)                    721 (10.30)    \<0.001
  Medication                                                         
   NSAIDs use          960 (41.06)                    2366 (33.73)   \<0.001

\*Urbanisation level from 1 to 4 indicates most to least urbanised.

NSAIDs, non-steroidal anti-inflammatory drugs.

During the 3-year follow-up period, 528 (3.21%) of the 9352 study patients experienced CKD, including 163 patients in the schizophrenia group and 365 patients in controls. The stratified Cox proportional hazard analysis showed that the schizophrenia group had a crude HR 1.36 times greater than that of the comparison group (95% CI 1.13 to 1.63; p\<0.001; [table 2](#BMJOPEN2014006777TB2){ref-type="table"}).

###### 

Individuals with and without schizophrenia as predictors of CKD identified by Cox regression

  Variable           Number (%) of individuals   
  ------------------ --------------------------- --------------
  With CKD           163 (6.90)                  365 (5.20)
  Without CKD        2175 (93.10)                6649 (94.80)
  Incidence rate\*   25.13                       18.6
  Crude HR           1.36 (1.13 to 1.63)†        

\*Incidence rate: per 1000 person-years.

†p\<0.001 for comparison between patients with two groups.

CKD, chronic kidney disease.

[Figure 2](#BMJOPEN2014006777F2){ref-type="fig"} depicts the CKD-free survival curves obtained by the Kaplan-Meier method, and shows that patients with schizophrenia had a significantly lower 3-year CKD-free survival than those without (log rank test, p\<0.05). There was a significant difference in the CKD distribution between these two cohorts in the 3-year follow-up. The incidence rate (per 1000 person-years) of CKD for patients with schizophrenia (25.13) was higher than that for non-schizophrenic controls (18.60).

![Chronic kidney disease (CKD) free survival for patients with schizophrenia (\-\--) and patients without schizophrenia (--) during the 3-year follow-up period in Taiwan from the index date.](bmjopen2014006777f02){#BMJOPEN2014006777F2}

After adjusting the age group, hypertension, diabetes mellitus, hyperlipidaemia, heart disease and NSAIDs usage, the Cox regression analysis showed that the elderly (HR=4.73; 95% CI 3.27 to 6.84; p\<0.001), hypertension (HR=1.41; 95% CI 1.13 to 1.75, p\<0.001), diabetes mellitus (HR=2.09; 95% CI 1.69 to 2.59; p\<0.001), heart disease (HR=1.35; 95% CI 1.10 to 1.66, p\<0.001) and NSAIDs usage (HR=3.21; 95% CI 2.64 to 3.93; p\<0.001); the HR for patients with schizophrenia was 1.25 (95% CI 1.04 to 1.50; p\<0.05). Most notably, patients with schizophrenia were found to be of an increased risk for the development of CKD, such as diabetes mellitus and the use of NSAIDs ([table 3](#BMJOPEN2014006777TB3){ref-type="table"}).

###### 

Independent predictors of CKD identified by Cox regression analysis

  --------------------------------------------------------------------
  Variable             Crude\                   Adjusted\
                       HR (95% CI)              HR\* (95% CI)
  -------------------- ------------------------ ----------------------
  Schizophrenia        1.36 (1.13 to 1.63)†     1.25 (1.04 to 1.50)‡

  Gender                                        

   Female              1                        --

   Male                1.13 (0.95 to 1.34)      --

  Age Group                                     

   18--29              1                        1

   30--39              1.75 (1.24 to 2.48)‡     1.65 (1.17 to 2.34)†

   40--49              2.99 (2.17 to 4.12)†     2.27 (1.64 to 3.16)†

   50--59              4.81 (3.45 to 6.70)†     2.82 (1.98 to 4.00)†

   60--69              8.44 (6.00 to 11.88)†    4.07 (2.80 to 5.91)†

   ≥70                 12.67 (9.19 to 17.47)†   4.73 (3.27 to 6.84)†

  Income                                        

   \<18 000            1                        --

   18 000--34 999      1.06 (0.88 to 1.27)      --

   ≥35 000             0.61 (0.45 to 1.82)†     --

  Urbanisation                                  

   1                   1                        --

   2                   0.88 (0.61 to 1.28)      --

   3                   1.15 (0.90 to 1.46)      --

   4                   1.18 (0.95 to 1.46)      --

  Geography                                     

   North               1                        --

   Central             1.10 (0.87 to 1.40)      --

   South               1.31 (1.08 to 1.59)†     --

   East                1.62 (0.99 to 2.66)      --

  Comorbidity                                   

   Hypertension        4.64 (3.91 to 5.50)†     1.41 (1.13 to 1.75)†

   Diabetes mellitus   5.15 (4.27 to 6.21)†     2.09 (1.69 to 2.59)†

   Hyperlipidaemia     2.97 (2.46 to 3.60)†     1.10 (0.89 to 1.35)

   Obesity             1.29 (0.53 to 3.11)      --

   Heart disease       3.96 (3.30 to 4.75)†     1.35 (1.10 to 1.66)†

  Medication                                    

   NSAIDs use          4.81 (3.97 to 5.83)†     3.21 (2.64 to 3.93)†
  --------------------------------------------------------------------

\*Each variable was adjusted for every other variable listed whose crude HR was significant (p\<0.05).

†p\<0.001 for comparison between patients with two groups.

‡p\<0.05 for comparison between patients with two groups.

NSAIDs, non-steroidal anti-inflammatory drugs.

All the 2338 patients with schizophrenia with treatment of antipsychotics were assessed during the 3 years from the diagnosis index date. There are 10 typical antipsychotics (chlorpromazine, clopenthixol, clothiapine, flupentixol, haloperidol, loxapine, pimozide, sulpiride, thioridazine and trifluoperazine) and seven atypical antipsychotics (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone and zotepine). Of the patients with schizophrenia, 808 (34.56%) were treated with a single antipsychotic, 1185 (50.68%) were treated with two or more different antipsychotics, and 345 (14.76%) were treated without any antipsychotics. As shown in [table 4](#BMJOPEN2014006777TB4){ref-type="table"}, the patients with schizophrenia using different antipsychotics are stratified by the total number of days the antipsychotics were used (never used, \<90 or ≧90 days). After adjusting for hypertension and diabetes mellitus, hyperlipidaemia and heart disease, neither typical antipsychotics nor atypical antipsychotics increased the risk of CKD.

###### 

The HR of CKD in patients with schizophrenia in relation to antipsychotics use during the 3-year follow-up period

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variable              Number of patients   Mean years use   Number of CKD   Incidence rate\*   Crude HR\             Adjusted HR†\
                                                                                                 (95% CI)              (95% CI)
  --------------------- -------------------- ---------------- --------------- ------------------ --------------------- ---------------------
  TA                    1299                 0.73             86              22.10              0.67 (0.47 to 0.94)   0.65 (0.46 to 0.92)

   Not used             694                  --               77              37.59              1                     1

  Amisulpride (days)    243                  0.48             16              10.90              --                    --

   Not used             1750                 --               147             23.69              1                     1

   \<90                 123                  0.09             8               21.54              0.35 (0.08 to 1.45)   0.35 (0.08 to 1.45)

   ≥90                  120                  0.87             8               22.06              0.54 (0.17 to 1.73)   0.55 (0.18 to 1.75)

  Aripiprazole (days)   174                  0.44             7               6.73               --                    --

   Not used             1819                 --               160             24.30              1                     1

   \<90                 101                  0.08             4               13.37              0.67 (0.21 to 2.12)   0.68 (0.22 to 2.15)

   ≥90                  73                   0.92             3               13.64              0.31 (0.04 to 2.19)   0.33 (0.04 to 2.33)

  Clozapine (days)      88                   0.68             3               5.69               --                    --

   Not used             1905                 --               160             23.97              1                     1

   \<90                 39                   0.09             2               17.28              0.59 (0.08 to 4.23)   0.58 (0.08 to 4.13)

   ≥90                  49                   1.16             1               6.76               0                     0

  Olanzapine (days)     386                  0.53             15              6.50               --                    --

   Not used             1607                 --               148             25.58              1                     1

   \<90                 198                  0.08             9               15.26              0.53 (0.22 to 1.32)   0.54 (0.22 to 1.33)

   ≥90                  188                  0.99             6               10.65              0.33 (0.10 to 1.06)   0.35 (0.11 to 1.11)

  Quetiapine (days)     454                  0.58             43              15.76              --                    --

   Not used             1539                 --               120             21.53              1                     1

   \<90                 240                  0.08             24              33.55              1.43 (0.81 to 2.53)   1.41 (0.80 to 2.51)

   ≥90                  214                  1.13             19              29.33              0.90 (0.43 to 1.87)   0.83 (0.40 to 1.74)

  Risperidone (days)    1066                 0.60             64              10.66              --                    --

   Not used             927                  --               99              25.17              1                     1

   \<90                 476                  0.09             32              22.70              0.93 (0.56 to 1.52)   0.94 (0.57 to 1.53)

   ≥90                  530                  1.12             32              20.07              0.59 (0.34 to 1.03)   0.59 (0.34 to 1.05)

  Zotepine (days)       232                  0.43             18              13.04              --                    --

   Not used             1761                 --               145             23.20              1                     1

   \<90                 144                  0.08             9               21.06              0.98 (0.43 to 2.25)   1.02 (0.44 to 2.34)

   ≥90                  88                   1.00             9               34.28              1.08 (0.40 to 2.93)   1.00 (0.36 to 2.72)
  ------------------------------------------------------------------------------------------------------------------------------------------

345 patients did not use any antipsychotic.

\*Incidence rate: per 1000 person-years

†Each variable was adjusted for hypertension, diabetes mellitus, hyperlipidaemia and heart disease.

‡p\<0.05 for comparison between patients with two groups.

TA, typical antipsychotics.

About 40% (41.06%, N=960) of the patients used any NSAIDs in the schizophrenia group, and 2366 (33.73%) used NSAIDs in the control group. The average prescription days of NSAIDs were 29 in the schizophrenia group and 30 in the control group. The patients with schizophrenia were stratified by comorbidities and NSAIDs usage in patients older than 65 years. After adjusting for NSAIDs usage, the patients had a higher HR in this group, as shown in [table 5](#BMJOPEN2014006777TB5){ref-type="table"}.

###### 

The HR of CKD in 2338 patients with schizophrenia for comorbidities and NSAIDs use during the 3-year follow-up period

  ------------------------------------------------------------------------------------------------------------------------------------
  Variable            Number of patients   Crude HR\              Adjusted HR\*\         Adjusted HR†\          Adjusted HR‡\
                                           (95% CI)               (95% CI)               (95% CI)               (95% CI)
  ------------------- -------------------- ---------------------- ---------------------- ---------------------- ----------------------
  *Comorbidity*                                                                                                 

  Hypertension        420                                                                                       

   \<65 years old     293                  1                      1                      1                      1

   ≥65 years old      127                  2.00 (1.23 to 3.25)§   1.85 (1.13 to 3.03)§   1.59 (0.96 to 2.63)    1.54 (0.93 to 2.56)

  Diabetes mellitus   218                                                                                       

   \<65 years old     173                  1                      1                      1                      1

   ≥65 years old      45                   3.83 (2.06 to 7.12)¶   3.66 (1.93 to 6.96)¶   2.56 (1.26 to 5.16)§   2.52 (1.25 to 5.09)§

  Dyslipidaemia       272                                                                                       

   \<65 years old     236                  1                      1                      1                      1

   ≥65 years old      36                   2.52 (1.13 to 5.65)    2.54 (1.09 to 5.92)§   1.78 (0.76 to 4.15)    1.90 (0.80 to 4.53)

  Heart disease       343                                                                                       

   \<65 years old     247                  1                      1                      1                      1

   ≥65 years old      96                   2.53 (1.50 to 4.30)¶   2.46 (1.44 to 4.20)¶   1.69 (0.96 to 2.99)    1.70 (0.96 to 3.00)

  *Medication*                                                                                                  

  NSAIDs use          960                                                                                       

   \<65 years old     835                  1                      1                      1                      1

   ≥65 years old      125                  2.82 (1.84 to 4.30)¶   2.82 (1.84 to 4.30)¶   1.83 (1.13 to 2.97)§   1.83 (1.13 to 2.97)§
  ------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted HR Adjusted for NSAIDs use.

†Adjusted HR Adjusted for hypertension, diabetes mellitus, dyslipidaemia and heart disease.

‡Adjusted HR Adjusted for hypertension, diabetes mellitus, dyslipidaemia, heart disease and NSAIDs use.

§p\<0.05 for comparison between patients with two groups.

¶p\<0.001 for comparison between patients with two groups.

NSAIDs, non-steroidal anti-inflammatory drugs.

Discussion {#s4}
==========

After adjusting for demographic characteristics, select comorbid medical disorders and NSAIDs usage, the current results reveal that patients with schizophrenia have an increased risk of nearly 40% (HR=1.36; 95% CI 1.13 to 1.63; p\<0.001) of developing CKD within a 3-year follow-up period after their schizophrenia diagnosis, as compared with that of the matched non-schizophrenic controls. There was a significant difference in the CKD distribution between these two cohorts in the 3-year follow-up period. This tendency was more evident since the enrolled patients with schizophrenia were newly diagnosed and had no previous history of CKD. No sex difference in the risk of developing CKD was found. To the best of our knowledge, there have been no previous studies showing this risk for the development of CKD. Since the Kaplan-Meier method revealed that patients with schizophrenia had a significantly lower 3-year CKD-free survival than those without schizophrenia, and it takes 540 days (18 months) to achieve a significantly adjusted HR (data not shown), hence 3 years proved to be a reasonable period to follow the newly-diagnosed patients with schizophrenia.

In the study population, the group with schizophrenia consisted of patients who were first entered into the record with a diagnosis of schizophrenia, with over 70% of this group being 30 years of age and/or older, which is beyond the typical age of the onset of schizophrenia, being that of males 18--25 years of age, and females 20--35 years of age.[@R14] [@R15] This disparity may be due to the fact that people with mental disorders tend to start searching for help from folk belief healers or their primary care physicians, such as internists or family physicians, before they visit a psychiatrist in Taiwan.[@R16] However, most of the Taiwanese folk belief healers provide shamanistic ritual treatment,[@R17] religious consultations[@R18] or support to patients and caregivers from their faith groups,[@R19] as well as to those patients with schizophrenia who seek their help, instead of medications.

The disadvantaged socioeconomic status and psychotic symptoms present in patients with schizophrenia can also result in poor food choices.[@R20] In the non-schizophrenic population, many with chronic illnesses, their treatments and even their medications usage can also contribute to the development of CKD: for example, comorbidity with diabetes mellitus, autoimmune diseases or nephritis; use of some nephrotoxic drugs[@R21]; or unhealthy lifestyles, obesity and the metabolic syndrome.[@R22] Therefore, unhealthy diets of low-fibre food, smoking habits, lack of exercise, disadvantaged socioeconomic status and metabolic syndrome may also contribute to the development of CKD among patients with schizophrenia.

Another potential interpretation could be that once individuals are diagnosed with schizophrenia, they are then subjected to closer medical attention, thus making diagnosis with CKD more likely. However, results varied about the study of frequency in the help-seeking behaviours of patients with schizophrenia or contacts with their general practitioners.[@R23] [@R24] Therefore, further study is needed to understand utilisations of preventive somatic diseases screening of patients with schizophrenia.

From the biological viewpoint, some previous studies have shown that endothelial dysfunction is common to the pathogenesis of DM, hypertension and hyperlipidaemia,[@R22] and also that endothelial dysfunction is an underlying pathophysiological condition of CKD.[@R25] Alteration of the endothelial function, as shown in one prior study, plays a role in patients with first-onset schizophrenia[@R26] another study revealed that some pharmacogenetic variability regarding folate and homocysteine metabolism may also increase endothelial dysfunction risk in patients with schizophrenia using atypical antipsychotics.[@R27] There is a statistically significant increase in the risk of CKD in patients with schizophrenia, and a possible common pathway involving an alteration of the endothelial function should be explored in further research.

Patients with schizophrenia need a long duration of, or even lifelong, antipsychotic treatment. Therefore, the association between antipsychotic use and CKD in patients with schizophrenia has been discussed in this study. We therefore found that there is no specific association between antipsychotic treatment and CKD when controlling for comorbidity with hypertension and diabetes mellitus.

Using NSAIDs is a well-known risk factor for CKD.[@R28] Several nationwide population-based studies showed that the use of NSAIDs in Taiwan\'s residents was generally around 40--50%, and could be up to 95% in some populations.[@R29] In a previous study, patients with schizophrenia were found to have the well-known phenomenon of pain insensitivity, or hypoalgesia, but its impact on their general health is unclear.[@R32] Some authors argue that patients with schizophrenia do have chronic pain.[@R33] However, the current findings suggest that the percentage of patients with schizophrenia with any previous NSAIDs usage is higher than that of the non-schizophrenia group, and therefore this phenomenon needs further study. In our study, patients with schizophrenia who had used NSAIDs had a higher HR (3.21, 95% CI 2.64 to 3.93; p\<0.001) in comparison to the control group. In the group of patients with schizophrenia, those with any NSAIDs usage had a higher adjusted HR than patients not receiving NSAIDs (HR=2.13; 95% CI 1.51 to 3.02; p\<0.001). Therefore, schizophrenia presents an increased risk for CKD, and the use of NSAIDs seems to have some synergistic effects for this mounting risk in these patients.

Current guidelines recommend the regular monitoring of metabolic risk in people treated with antipsychotic medication, such as fasting glucose, body mass index, fasting triglycerides, fasting cholesterol, girth, high-density/low-density lipoprotein, blood pressure and symptoms of diabetes.[@R34] From the aspects of cost-effectiveness, screening combined blood urine nitrogen and creatinine tests in patients with schizophrenia once a year would cost about NT\$80 (New Taiwan dollars), equivalent to US\$2.67 per patient-year, as compared to haemodialysis US\$1325 per patient-year for patients without diabetes with end-stage renal disease (ESRD), and \$4677 per patient-year for patients with diabetes with ESRD in Taiwan. These tests would allow physicians to initiate early prevention for patients with schizophrenia who are at risk of developing CKD.[@R35] However, further study is required to evaluate the benefits of screening CKD in patients with schizophrenia.

Studies using insurance claims data have some limitations: patients with CKD have been detected, but the severity and outcomes are not clear in such a data set. The antipsychotic dose, degree of smoking and alcohol use, dietary habits and the amount of NSAID or other analgesics, such as acetaminophen usage, are not known in the health data set. Adequate accessibility to and availability of treatment in the disadvantaged patient group with schizophrenia are in doubt, since inequalities in healthcare provision for people with schizophrenia have been documented.[@R36] [@R37] In addition, an even longer follow-up is needed to clarify the long-term risk for patients with schizophrenia of developing CKD in this population. Although periodic renal function tests are recommended for patients with schizophrenia, the future cost-effectiveness of such tests needs further study.

Conclusions {#s5}
===========

In this national population-based retrospective cohort study, we found a significant association, a 25% increased risk, between schizophrenia and subsequent CKD in a 3-year follow-up period, especially in those older ages, those with DM and those using NSAIDs. Further study is required to extend this positive link to clinical purposes, thereby not only establishing preventive treatment, but also by evaluating the benefits of screening CKD in patients with schizophrenia.
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